Entries |
Document | Title | Date |
20080226699 | Method and System for Rapid Transdermal Administration - Invention relates to a method for transdermal delivery of a topically applied physiologically active agent comprising: providing a micro-projection apparatus comprising an array of microprojections ( | 09-18-2008 |
20080226700 | Medicated Gauze - The present invention relates to a medicated gauze containing as active ingredient, aliantoin, a Centella Asiatica extract and, optionally, an Urtica dioica extract. | 09-18-2008 |
20080226701 | MEDICATED PATCHES - An athletic head gear having a hard outer shell, at least one soft inner padding cushioning the head of a user from the hard outer shell, and a medicated patch including an adhesive layer contacting the soft inner padding, and a medicated layer for contacting the user's skin, where the medicated patch includes a medicament useful for treating or preventing acne. | 09-18-2008 |
20080226702 | Transdermal Delivery Form Disposal Systems and Methods - The extraction and use of residual opioids from transdermal dosage forms can be reduced by placement and fixation of used dosage forms onto a surface. The used dosage form can be fixed to the surface such that it cannot be removed without at least partially destroying the matrix containing the opioid, or such that the matrix containing the opioid is rendered at least partially inaccessible to opioid extraction methods. The disposal system for one or more opioid-containing transdermal delivery forms comprises at least one disposal surface for receiving the transdermal delivery form. The at least one disposal surface can comprise one or more structures for fixing a transdermal delivery form to the at least one surface. Alternatively, the transdermal delivery form comprises one or more structures for permanently fixing the transdermal delivery form to the surface. The disposal system can also be used for preventing or reducing diversion of opioids from transdermal delivery forms. | 09-18-2008 |
20080226703 | Human Growth Hormone Patch Formulations - The invention encompasses a transdermal patch formulation comprising hGH, at least one sugar, one amino acid or polyol, and a buffer, wherein the buffer maintains the pH of the formulation in the range of about 5 to about 9 and the formulation does not contain both glycine and mannitol. | 09-18-2008 |
20080233180 | Transdermal Patch and Method For Delivery Of Vitamin B12 - The present invention is directed to compositions and devices for transdermally administering vitamin B | 09-25-2008 |
20080241231 | TRANSDERMAL DELIVERY OF DEXAMETHASONE AND PROMETHAZINE - Relief or prophylaxis from nausea and/or emesis are provided by transdermal compositions comprising dexamethasone and promethazine. The transdermal compositions are in the form of transdermal solutions and/or suspensions, such as lotions, pastes, gels, ointments or transdermal patches. | 10-02-2008 |
20080254107 | METHOD AND DEVICE FOR TREATING BURSITIS - The present invention relates to a method for treating a subject for a condition or inflammation associated with oedema, excess body fluids or oedema and excess body fluids, or for treating a subject for an abscess, boil, blister or cyst. The method comprises applying to the skin surface covering a body part or region affected by said condition, inflammation, abscess, boil, blister or cyst a composition capable of transdermally attracting fluids from the body part or region or its proximity, wherein said composition comprises at least one adsorptive or absorptive agent, and leaving said composition in contact with the skin for sufficient time to allow said composition to transdermally absorb or adsorb at least a portion of the body fluids from said body part or region. The present invention also relates to compositions for absorbing or adsorbing fluids from a body part or region, and which are capable of transdermally attracting fluids from body parts or regions or their proximity. | 10-16-2008 |
20080260811 | Transdermal delivery systems - Transdermal delivery systems for administering sufentanil through the skin are provided. The systems contain a sufficient amount of sufentanil to induce and maintain a constant state of analgesia when applied to a subject. The systems are characterized as having one or more features including a high degree of dosage form rate control over flux of sufentanil from the system, a high net flux of sufentanil from the system through the skin, lack of a permeation enhancer, an adhesive member demonstrating superior shear time, a low coefficient of variation in the net flux of sufentanil from the system, a high delivery efficiency, and a substantially constant steady state net flux of sufentanil from the system. Methods of using the transdermal delivery systems to administer a sufficient amount of sufentanil to induce and maintain analgesia for extended periods when applied to a subject are also provided. | 10-23-2008 |
20080274166 | Patch for Transdermal Drug Delivery - Apparatus is provided including a transdermal drug delivery patch product (10, 100), which includes a patch ( | 11-06-2008 |
20080274167 | TRANSDERMAL THERAPEUTIC SYSTEM (TTS) WITH FENTANYL AS ACTIVE INGREDIENT - The invention relates to transdermal therapeutic systems with fentanyl or an analogous fentanyl derivative as active ingredient. In order to prevent inadvertent overdosage by uncontrolled release of active ingredient as a result of damage, the active ingredient is contained in fluid-filled micro-reservoirs in the layer containing the active ingredient. The layer containing the active ingredient can optionally be provided with a membrane. | 11-06-2008 |
20080274168 | TRANSDERMAL DELIVERY DEVICE DISPOSAL SYSTEM - The present invention relates to a transdermal delivery device disposal system for disposing of a transdermal delivery device containing at least one pharmaceutically active component. The disposal system contains at least one sheet or substrate on which an adhesive is coated; and one or more of the following components: (a) monomer, and optionally comonomer(s), to be polymerized; (b) an initiator, and optionally co-initiator(s), to initiate the polymerization; (c) at least one crosslinking agent to crosslink the (co)polymer; and (d) at least one deactivating agent to chemically alter, to degrade, and/or to deactivate the active component(s) contained in the transdermal delivery device, such as an opioid antagonist or an opioid agonist deactivating agent so that the euphoric effects of the active component(s) contained in the transdermal delivery device are at least temporarily inhibited, diminished, or halted in vivo, wherein at least one adhesive-coated sheet or substrate adheres to, immobilizes, or isolates, and prevents, inhibits, or diminishes the misuse or abuse of the active component contained in, at least one transdermal delivery device. | 11-06-2008 |
20080279915 | Matrix-Controlled Transdermal Therapeutic System Based on an Adhesive for Administering Norelgestromin or the Combination Thereof with an Estrogen - The invention relates to a transdermal therapeutic system comprising an active-ingredient-impermeable top layer, an active-ingredient-containing matrix and a removable protective layer, the matrix comprising or consisting of norelgestromin and an optional oestrogen as active ingredients as well as also a pressure-sensitive hot-melt adhesive and optional auxiliaries. | 11-13-2008 |
20080286348 | Secured transdermal delivery system - A secured transdermal delivery system, applicable to both matrix and reservoir patches, for preventing misuse of medications embedded within and affixed to transdermal patches. The secured transdermal delivery system includes a backing supporting a pharmaceutical composition and one or more security agents adapted to modify the pharmacophore of the pharmaceutical composition. The security agent is separated from the pharmaceutical composition by one or more dissolving security layers which define one or more security reservoirs within the patch. | 11-20-2008 |
20080286349 | SYSTEMS, DEVICES, AND METHODS FOR PASSIVE TRANSDERMAL DELIVERY OF ACTIVE AGENTS TO A BIOLOGICAL INTERFACE - Systems, devices, and methods for transdermal delivery of one or more therapeutic active agents to a biological interface. A transdermal drug delivery system is provided for passive transdermal delivery of one or more ionizable active agents to a biological interface of a subject. A transdermal drug delivery system includes a backing substrate, and an active agent layer. The active layer includes a thickening agent, a plasticizer, and a therapeutically effective amount of an ionizable active agent. | 11-20-2008 |
20080292684 | Device for Delivery of Active Principles - A device for the delivery of active principles for dermal and, in particular, transdermal application having the form of a two-layered patch consisting of a first layer having a homogeneous composition and comprising at least one active principle, a water-soluble film-forming agent and a hydrophilic adhesive polymer, and of a second layer joined in a permanent manner to the first and having a water vapour permeability of less than 500 g/m | 11-27-2008 |
20080292685 | Transdermal Patch Containing Isosorbide Dinitrate and Bisoprolol - This invention relates to a transdermal patch in the form of a layer complex, comprising a backing layer, a drug-reservoir layer comprising pharmacologically active ingredients and pharmaceutically acceptable adjuvants, and a release liner covering the drug-reservoir layer, characterized in that the drug-reservoir layer comprises isosorbide dinitrate and Bisoprolol at a ratio of 1:3 to 3:1 by weight, as the pharmacologically active ingredients. Animal tests show that said patch can reduce the elevation of T wave of cardiogram, the increase of the level of myocardial enzyme in blood serum, and the extension of the range of myocardial infarction caused by ligating the coronary artery in animals. Results show that said patch exhibits a considerable synergistic effect in the treatment of cardiovascular diseases and has good preventive and therapeutic effects on several adverse events on heart. In addition, the animal tests show that the patch according to the invention has a better pressure-reducing effect than the application of the patch containing only one of isosorbide dinitrate and Bisoprolol, and does not worsen the arrhythmia that is easily caused by the application of the patch containing only isosorbide dinitrate or Bisoprolol. | 11-27-2008 |
20080305154 | Transdermal medicament patch and active electrode for same - A transdermal medicament patch includes a biocompatible substrate having a therapeutic face on one side configured for disposition against the skin of a patient, a biocompatible adhesive on the therapeutic face, a planar medicament matrix covering a portion of the therapeutic face, and a release liner covering the portion of therapeutic that is not obscured by the medicament matrix. An aperture formed through the release sheet affords direct access by medicament to the entire surface of the medicament matrix opposite from the therapeutic face of the substrate. An active electrode positioned between the medicament matrix and the therapeutic face of the substrate includes an electrically conductive backing layer positioned against the therapeutic face of the substrate and a pH-control layer covering less than all of the side of the backing layer opposite from the therapeutic face of the substrate. One active electrode design criterion relates the relative size of the pH-control layer to the size of the backing layer; another relates the size of portion of the area of the backing layer that is free of the pH-control lawyer to the size of the pH-control layer. The pH-control layer is made of an electrically conductive material capable of moderating changes in the hydrogen-ion concentration in the medicament matrix during iontophoretic current flow. An electrical contact electrically coupled through the substrate to the backing layer includes a hollow, electrically conductive snap fitting having an open end and a cooperating stud that is inserted into the open end of the snap. | 12-11-2008 |
20080305155 | Transdermal Systems Containing Multilayer Adhesive Matrices to Modify Drug Delivery - A transdermal drug-containing dosage unit comprises: a backing layer substantially impervious to the drug to be delivered transdermally; a first polymeric adhesive matrix, in contact with the backing layer, having dispersed therein the drug and having a first delivery profile of the drug; a second polymeric adhesive matrix, in contact with said first polymeric adhesive matrix, having dispersed therein the drug and having a second delivery profile of the drug, wherein said second delivery profile is different from said first delivery profile; and a release liner in contact with the second polymeric adhesive matrix. | 12-11-2008 |
20080311179 | SULFONYLPYRAZOLE AND SULFONYLPYRAZOLINE CARBOXAMIDINE DERIVATIVES AS 5-HT6 ANTAGONISTS - This invention concerns compounds of the general formula (1). | 12-18-2008 |
20080311180 | Method of Preventive On-Demand Hormonal Contraception - The invention relates to a method of hormonal female controlled on-demand contraception in which a pharmaceutical preparation comprising at least one progestogen is administered transdermally on demand and on a single occasion prior to anticipated sexual intercourse. | 12-18-2008 |
20080317832 | TRANSDERMAL DELIVERY SYSTEM COMPRISING GLYCOPYRROLATE TO TREAT SIALORRHEA - In one aspect, the invention includes a method for treating sialorrhea, comprising the steps of identifying a patient afflicted with sialorrhea and administering a therapeutically effective amount of glycopyrrolate to the patient using a transdermal route of administration. In another aspect, the invention is a transdermal drug delivery system for treating a patient exhibiting sialorrhea, including a transdermal patch, a therapeutically effective amount of glycopyrrolate contained in the transdermal patch to alleviate sialorrhea, and a pharmaceutically acceptable carrier. The transdermal patch can be a single layer drug-in-adhesive patch, a multi-layer drug-in-adhesive patch, a matrix patch, or a reservoir patch. | 12-25-2008 |
20080317833 | Novel Anti-Inflammatory Androstane Derivatives - There are provided according to the invention pharmaceutical compositions comprising a compound of formula (I) | 12-25-2008 |
20090004257 | TRANSDERMAL ADMINISTRATION OF FENTANYL AND ANALOGS THEREOF - A method and a non-rate controlled, monolithic, subsaturated patch for transdermally administering fentanyl and analogs thereof, for analgetic purposes, to a subject through skin over an extended period of time are disclosed. | 01-01-2009 |
20090010998 | Drug-delivery patch comprising a dissolvable layer and uses thereof - The present invention provides a drug-delivery patch having at least one dissolvable layer comprising an active material and an adhesive backing or cover. The present invention also provides a method of transdermally vaccinating an animal by ablating an area of the stratum corneum of the animal and applying the patch described herein to the area. | 01-08-2009 |
20090017102 | Enhancing transdermal delivery of opiod antagonists and agonistis using codrugs links to bupropion or hydroxybupropion - The present invention is directed to novel codrugs comprising bupropion or hydroxybupropion and an opioid antagonist or an opioid agonist joined together by chemical bonding. The codrugs provide a significant increase in the transdermal flux across human skin, as compared to the basic opioid antagonist or opioid agonist. | 01-15-2009 |
20090035357 | Method of drug delivery using a transdermal device having a phase change material - A method of drug delivery utilizes a transdermal device that contains a phase change material and a first material such as a drug, a pharmaceutical, or a medicament mixed with or disposed near the phase change material. The phase change material is one that transitions from solid to liquid form when heated. A second material is disposed, suspended, or held in the solid form of the phase change material. The phase change material changes to a liquid state in response to heat and the second material that is disposed, suspended, or held in the phase change material is released and comes into contact with the first material. Advantageously, such second materials may include substances such as pharmaceuticals that boost or supplement the effect produced by a drug delivered transdermally by the device, or drug antagonists, or nicotine. | 02-05-2009 |
20090041832 | Adhesive mixture for transdermal delivery of highly plasticizing drugs - Transdermal drug delivery patches and methods of their production are described. The patches can be made such that the accommodate highly plasticizing drugs such as selegiline and/or the use of protonated forms of various drugs. | 02-12-2009 |
20090047334 | TRANSDERMAL PATCH FOR EXTENDED DELIVERY OF CALCIUM - The present invention relates to a method for delivery of calcium that avoids the problems with orally given calcium tablets. Particularly, the present invention is a transdermal patch for providing between 40 mg and 500 mg of bioavailable calcium to a patient. | 02-19-2009 |
20090053289 | KIT FOR THE TREATMENT OF A CORN OR CALLUS - The present invention is a kit for use by a person to apply a daily treatment of medication and therapy to remove a corn or callus from the person's skin while providing maximum comfort to the person and minimal damage to healthy skin. In one embodiment, the kit comprises a box, an AM treatment system, and a PM treatment system for application at night. The AM treatment system comprises a plurality of AM foam bandages each having a medicated foam pad of hydrocolloid. The PM treatment system comprises a plurality of PM foam protective covers and a plurality of PM medicated non-woven patches impregnated with salicylic acid. The PM treatment system allows the person to remove a single PM medicated patch, trim it to fit the shape of the corn, and position it as desired over the corn. The person may then remove a single PM foam protective cover and apply it over the PM medicated patch, covering it completely, thereby limiting migration of the salicylic acid to healthy skin. Upon removal of the PM foam protective cover, the PM medicated patch along with a portion of the dead skin is removed neat and clean. The treatment cycle begins anew, wherein the AM foam bandage has the opportunity to heal any healthy skin that my have inadvertently come into contact with the salicylic acid of the PM treatment system as well as softening additional dead skin of the corn prior to the application of the next PM treatment system. | 02-26-2009 |
20090053290 | TRANSDERMAL DRUG DELIVERY COMPOSITIONS AND TOPICAL COMPOSITIONS FOR APPLICATION ON THE SKIN - Transdermal delivery compositions and topical compositions for application to the skin are provided. The transdermal delivery composition includes at least two penetrants working synergistically but by disparate biochemical pathways. In one embodiment, the transdermal delivery system includes benzyl alcohol and lecithin organogel. The transdermal delivery compositions are used in a variety of topical compositions as a means of transdermally delivering and topically administering different drugs and agents, including compositions promoting collagen biosynthesis, retinoids and skin lighteners, chemical denervation agents such as BOTOX®, anti-fungal agents, anesthetics and non-steroidal anti-inflammatory drugs (NSAIDs). In addition, these topical compositions may be used in combination with non-ablative treatment modalities, such as microdermabrasion, laser-based skin remodeling and radio-frequency-based skin remodeling. | 02-26-2009 |
20090074844 | TRENADERMAL ABSORPTION PREPARATION - The present invention relates to a blood concentration regulation type percutaneous absorption preparation, which comprises an ester form of 4-{[2-((1R,2R,3R)-3-hydroxy-2-{(1E,3S)-3-hydroxy-4-[3-(methoxymethyl)phenyl]but-1-enyl}-5-oxocyclopentyl)ethyl]sulfanyl}butanoic acid and a base for external preparations. The blood concentration regulation type percutaneous absorption preparation of the present invention can stably maintain blood concentration of the active form of the present invention and is safe since there are no side effects. Therefore, it can be used as a percutaneous absorption preparation which can be persistently administered. | 03-19-2009 |
20090074845 | TRANSDERMAL ACTIVE PRINCIPLE DELIVERY MEANS - A transdermal active principle delivery means comprises a skin adherent or otherwise skin-tolerant substrate applicable to a skin area affected by DNA virus, which substrate includes a composition for treating DNA comprising a transdermally effective carrier medium including at least one active principle selected from the group consisting of diuretic agents and/or cardiac glycoside agents. | 03-19-2009 |
20090074846 | Patch containing a medicament - A patch containing a medicament comprises a release paper oppositely lying on the surface of a patch carrier. The release paper is defined to, from right to left, a first teardown slice, a second teardown slice, and a third teardown slice. Each teardown slice correspondingly matches with an adjacent edge of another teardown slice through joints of concaves and convexes. The second teardown slice is close to the adjacent edges of the first teardown slice and third teardown slice, in which two pairs of smaller convex unit margins are oppositely symmetrical, and between the two pairs of smaller convex unit margins, each pair of larger concave unit margins are oppositely symmetrical to make the release paper stably and securely adhere to a carrier. For the functional effect of a product, the curve is unlikely complicated making a trouble to a user in tearing down the patch. | 03-19-2009 |
20090104253 | Hemostatic biocidal dressing - A hemostatic biocidal dressing includes pro-coagulant and biocidal agents providing a physical barrier to bleeding as well as chemical action to promote blood coagulation and thereby arrest coverage. At the same time, biocidal properties of the dressing prevent the introduction of infected agents and the establishment of infection within wounded tissue. A silverized textile provides biocidal action while a granulated hemostatic agent disposed within interstitial regions between polymer fibers provides coagulating action. | 04-23-2009 |
20090110718 | Derivatives of tiacumicin B as anti-cancer agents - New derivatives of tiacumicin B are disclosed and are presented by the general formula: | 04-30-2009 |
20090123527 | METHOD OF INDUCING TOPICAL ANESTHESIA AND TRANSDERMAL PATCH - Disclosed is a method of inducing topical anesthesia in a tissue or organ of an animal comprising providing an aqueous gel formulation comprising water, an anesthetic (e.g., lidocaine hydrochloride), a viscoelastic polymer, and a tonicity modifier, wherein the aqueous gel formulation is free of preservatives and phosphate buffer, is isotonic with physiological fluids, and is sterile and has low particulate count. Also disclosed are a transdermal patch comprising the aqueous gel formulation suitable for applying on the skin of a patient and a method of controlling pain therewith. | 05-14-2009 |
20090123528 | TRANSDERMAL DELIVERY OF BENEFICIAL SUBSTANCES EFFECTED BY A HOSTILE BIOPHYSICAL ENVIRONMENT - The present invention generally relates to the transdermal delivery of substances and, in some embodiments, to the transdermal delivery of beneficial substances by a hostile biophysical environment. In one aspect, various methods for the transdermal delivery of beneficial substances are disclosed. By creating a hostile biophysical environment, beneficial substances may be delivered, according to certain embodiments, through the stratum corneum of the skin into the body. Beneficial substances include, but are not limited to, pharmaceutical agents, drugs, vitamins, co-factors, peptides, dietary supplements, and others. The beneficial effects disclosed include, for instance, relief of pain and inflammation, prevention and healing of ulcers of the skin, relief of headache, improved sexual function and enjoyment, growth of hair on the scalp, improving muscle size and/or function, removing body fat and/or cellulite, treating cancer, treating viral infections and others. A hostile biophysical environment may also be used in conjunction with systems and methods for increasing local blood flow, according to one set of embodiments. For example, by using a nitric oxide donor such as L-arginine, local blood flow may be increased, e.g., by transdermally delivering the nitric oxide precursor. The nitric oxide donor may be the sole cause of increased blood flow, or it may be supplemented with an adjunct such as theophylline. | 05-14-2009 |
20090130189 | MEANS FOR TRANSDERMAL ADMINISTRATION OF NICOTINE - Devices for transdermal administration of nicotine, which provide for basic as well as additional user activatable administration of nicotine, as well as use of such devices. | 05-21-2009 |
20090130190 | Transdermal System for the Delivery of Sufentanil and Its Analogs - Methods and systems for the transdermal delivery of sufentanil and its analogs are described, from patches having a unique pharmacodynamic profile that can be used to treat persistent pain over extended periods and acute pain episodes of limited duration. | 05-21-2009 |
20090142390 | TRANSDERMAL SYSTEMS CONTAINING MULTILAYER ADHESIVE MATRICES TO MODIFY DRUG DELIVERY - A transdermal drug-containing dosage unit comprises: a backing layer substantially impervious to the drug to be delivered transdermally; a first polymeric adhesive matrix, in contact with the backing layer, having dispersed therein the drug and having a first delivery profile of the drug; a second polymeric adhesive matrix, in contact with said first polymeric adhesive matrix, having dispersed therein the drug and having a second delivery profile of the drug, wherein said second delivery profile is different from said first delivery profile; and a release liner in contact with the second polymeric adhesive matrix. | 06-04-2009 |
20090155343 | Tamsulosin-Containing Transdermal Patch - A tamsulosin-containing transdermal patch. A transdermal patch comprising a backing-layer and an adhesive layer on the backing-layer, characterized in that the adhesive layer contains an acrylic adhesive, further contains tamsulosin as an active ingredient in an amount of 0.1 to 20% by mass of the total mass of the adhesive layer and, if desired, a polyoxyethylene alkyl ether which is an additive playing a role in increasing solubility and a propylene glycol fatty acid ester which is an additive playing a role in promoting percutaneous absorption is provided. Further, a transdermal patch comprising a backing-layer and an adhesive layer on the backing-layer, characterized in that the adhesive layer contains a synthetic rubber adhesive, further contains tamsulosin as an active ingredient in an amount of 0.1 to 20% by mass of the total mass of the adhesive layer and a propylene glycol fatty acid ester which is an additive playing a role in promoting percutaneous absorption is provided. | 06-18-2009 |
20090169606 | Low Flexural Strength Transdermal Tobacco Alkaloid Patch - The invention relates to a tobacco alkaloid patch for transdermal administration of a tobacco alkaloid, said patch comprising an impermeable backing ( | 07-02-2009 |
20090175927 | Administration of cells and cellular extracts for rejuvenation - The invention describes methods and agents for improving cosmetic appearance, for promoting, improving or restoring health of cells and tissues, preferably skin, and more preferably, for restoring aged or damaged skin to a healthy appearance. This invention relates to the use of cells and cellular extracts in rejuvenation and healing technologies thereby improving healing and regeneration of all bodily tissues and organs. The present invention relates to compositions and methods of managing, preventing, and treating scars. The invention also relates to prevention of deterioration, damage and malfunction of cells and tissues, and to promote, improve or exceed cellular function in order to promote, improve and exceed appearance, vitality and health. In some embodiments, the invention relates to compositions of cells, eggs, cell extracts, egg extracts, and extract components such as purified nucleic acids, polypeptides, lipids, carbohydrates or other natural products. Said components can also be synthesized. In other embodiments, the cells are differentiable cells preferably stem cells or eggs. In some embodiments, compositions are used in a method that comprises application of compositions to tissues, including skin and/or wounds after removal of tissue surface layers. In other embodiments, the invention relates to methods of dedifferentiation of cells and/or dedifferentiation followed by differentiation. In other embodiments, the invention relates to managing, preventing, and treating skin diseases. | 07-09-2009 |
20090175928 | Lip Plaster - The invention relates to a self-adhesive lip plaster which comprises at least one single-layered matrix and which contains at least one antiviral active medical substance for using in the event of Herpes labialis. Said matrix is arranged on a flexible carrier film which is hydrophobic and also permeable to vapor. | 07-09-2009 |
20090175929 | Transdermally absorbable Donepezil Preparation - Disclosed is a donepezil-containing transdermally absorbable preparation which develops reduced adverse side effects and shows a satisfactory level of therapeutic effect. The preparation comprises an adhesive and a donepezil component (containing crystalline donepezil having type-B crystal polymorphism) and/or a salt thereof, wherein the donepezil component or the salt thereof is contained in an amount of 9 to 50% by mass relative to the total weight of the adhesive. The preparation (particularly, one having a non-aqueous adhesive layer) shows an excellent penetration of donepezil and/or a salt thereof into the skin, retains good stability of the active ingredient therein, and is remarkably reduced in local stimulation and adverse side effects. | 07-09-2009 |
20090186072 | Operational status for active transdermal medicament patch - An active transdermal medicament patch includes a planar substrate with a therapeutic face releasably retainable against the skin of a patient. A return electrode and a medicament matrix susceptible to permeation by medicament are secured at separated locations on the therapeutic face and electrically conductively engage the skin. A detector monitors iontophoretic medicament migration into the skin. An integrator operating on the output of the detector produces a running cumulative total of the amount of medicament delivered during a plurality of temporally non-contiguous therapy subsessions. A circuit breaker terminates medicament migration, when the output of the integrator equals a predetermined medicament quantity. A timer active during medicament migration stimulates a driver to operate a light-emitting diode in a distinct delivery confirmation mode during each a sequence of non-overlapping predetermined therapy subsessions, respectively. A circuit board on the substrate in a compact, folded state bears interconnected electrical circuit components. | 07-23-2009 |
20090196911 | Silicone Acrylate Hybride Composition and Method Of Making Same - A silicone acrylate hybrid composition includes the reaction product of a silicon-containing pressure sensitive adhesive composition, an ethylenically unsaturated monomer, and an initiator. The silicon-containing pressure sensitive adhesive composition includes acrylate or methacrylate functionality. A method of making the hybrid composition includes polymerizing the ethylenically unsaturated monomer and the silicon-containing pressure sensitive adhesive composition in the presence of the initiator. | 08-06-2009 |
20090208561 | TRANSDERMAL THERAPEUTIC SYSTEM - The present invention relates to a transdermal therapeutic system for the controllable release of an active ingredient, particularly a substance promoting wound healing, to a chronic wound or for chemotherapy, with at least one waveguide, wherein the active ingredient is deposited on the waveguide via a bond that is cleavable by electromagnetic pulses in the waveguide. | 08-20-2009 |
20090214624 | TOPICAL NITRIC OXIDE DONOR DEVICES AND METHODS FOR THEIR THERAPEUTIC USE - The present invention is related to topical nitric oxide delivery systems, and to using the same for mitigating or remediating various disease states The present invention is also related to using topical nitric oxide delivery systems for enhancing blood flow. | 08-27-2009 |
20090214625 | DRUG DELIVERY PATCH - The site to which a patch was stuck may be identified even after the patch is removed. | 08-27-2009 |
20090220580 | Percutaneous Absorption Formulation - The present invention provides a percutaneous absorption formulation including a patch having an adhesive layer disposed on a substrate and the adhesive layer contains ketotifen fumarate and tris(hydroxymethyl)aminomethane, and the patch is packaged in a hygroscopic packaging material. In the percutaneous absorption formulation, tris(hydroxymethyl)aminomethane particularly selected from various basic substances is incorporated, and by packaging the patch in a hygroscopic packaging material, the percutaneous absorptivity and content stability of a drug can be simultaneously improved and the yellowing of the drug can be suppressed. These effects can be further improved by the incorporation of propyl gallate, the use of an adhesive layer including an SIS-based adhesive base and a rosin ester-based adhesion imparting resin, and/or the removal of oxygen from the atmosphere in the inside of the packaging material. | 09-03-2009 |
20090226507 | HYDROXIDE-RELEASING AGENTS AS SKIN PERMEATION ENHANCERS - A method is provided for increasing the permeability of skin or mucosal tissue to topically or transdermally administered pharmacologically or cosmeceutically active agents. The method involves use of a specified amount of a hydroxide-releasing agent, the amount optimized to increase the flux of the active agent through a body surface while minimizing the likelihood of skin damage, irritation or sensitization. Topically applied formulations and drug delivery devices employing hydroxide-releasing agents as permeation enhancers are provided as well. | 09-10-2009 |
20090232879 | Thyromimetics for the Treatment of Fatty Liver Diseases - The present invention is directed toward the use of thyromimetic compounds that are thyroid receptor ligands, pharmaceutically acceptable salts thereof, and to prodrugs of these compounds for preventing, treating, or ameliorating fatty liver diseases such as steatosis, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis. | 09-17-2009 |
20090238861 | FENTANYL SUSPENSION-BASED SILICONE ADHESIVE FORMULATIONS AND DEVICES FOR TRANSDERMAL DELIVERY OF FENTANYL - Silicone adhesive formulations are provided, in which fentanyl particles are suspended one or more a solvated silicone adhesives. The formulations can be used for manufacturing improved, matrix-type transdermal devices for administering fentanyl. | 09-24-2009 |
20090246264 | Transdermal Tobacco Alkaloid Patch - The invention relates to a tobacco alkaloid patch ( | 10-01-2009 |
20090246265 | ABUSE DETERRENT TRANSDERMAL FORMULATIONS OF OPIATE AGONISTS AND AGONIST-ANTAGONISTS - Described herein are compositions comprising opioids, opioid antagonists and prodrugs of the same, formulations comprising opioids, opioid antagonists and prodrugs of the same, and methods of using opioids, opioid antagonists and prodrugs of the same. One embodiment described herein relates to the transdermal administration of a buprenorphine and encapsulated naltrexone in an abuse-resistant formulation for treating and preventing diseases and/or disorders. | 10-01-2009 |
20090246266 | PREPARATION AND COMPOSITION OF MELOXICAM TRANSDERMAL DRUG DELIVERY SYSTEM - A composition for transdermal permeation and a preparation method are disclosed. The composition including meloxicam as an active ingredient and further including at least one permeation enhancing agent selected from the group consisting of a sorbitan fatty acid derivative, a polyglyceryl fatty acid derivative, a polyethylene glycol vegetable oil ester, a polyethylene glycol corn oil glyceride, and a polyethylene glycol almond oil glyceride and at least one acrylic polymer adhesive having a hydroxyl group or no functional group. | 10-01-2009 |
20090258061 | ONCE-A-DAY REPLACEMENT TRANSDERMAL ADMINISTRATION OF FENTANYL - A method and a daily replacement patch for transdermally administering an opioid for analgesic effect. The patch is applied to a subject to deliver the opioid through the skin. The patch may be replaced daily and over an extended period of time. | 10-15-2009 |
20090258062 | Transdermal Therapeutic System Comprising Active Ingredient Particles and Having Increased Active Ingredient Flux - The invention relates to a transdermal therapeutic system, preferably a transdermal patch, having an active ingredient-containing matrix formed substantially of a water-insoluble base material, such as rubber and synthetic polymers, into which is incorporated water-soluble and/or water-swellable inclusion bodies, e.g. inclusion bodies formed from polyvinyl alcohol or polyethylene glycol, that further include micronized or nanoscale active ingredient particles. | 10-15-2009 |
20090258063 | Transdermal patch - The present invention provides a transdermal patch having excellent preservation stability and transdermal absorbency of DMAEs. The patch has a support and a plaster layer integrally laminated on one surface of the support, and the plaster layer includes: DMAEs; an acrylic adhesive prepared by copolymerizing monomers respectively containing 30 to 99% by weight of alkyl methacrylate having an alkyl group with a carbon number of 6 to 22 and 1 to 70% by weight of alkyl acrylate having an alkyl group with a carbon number of 2 to 20; and fatty acid ester prepared by dehydro-condensing saturated fatty acid having an alkyl group with a carbon number of 10 to 20 and saturated aliphatic monohydric alcohol having an alkyl group with a carbon number of 2 to 20, wherein solubility of the DMAEs is 0.05 to 5 g at 25° C. with respect to the fatty acid ester. | 10-15-2009 |
20090291126 | ADHESIVE PHARMACEUTICAL PREPARATION CONTAINING BISOPROLOL - An adhesive pharmaceutical preparation which has a less irritation to the skin surface, keeps excellent stability of bisoprolol in the preparation, and allows continuous administration of a pharmacologically effective amount of bisoprolol into the living body, is provided. The adhesive preparation | 11-26-2009 |
20090291127 | TRANSDERMAL ANTI-DEMENTIA ACTIVE AGENT FORMULATIONS AND METHODS FOR USING THE SAME - A transdermal antidementia active agent formulation is provided. In certain embodiments, the formulation includes a backing, an active agent reservoir layer including an antidementia active agent, wherein the antidementia active agent is present as both a freebase and optionally also present as a salt, an adhesive layer including the antidementia active agent, and optionally an adhesive overlay. Also provided are methods of using the formulations, e.g. for administering an antidementia active agent to a subject, and kits containing the formulations. | 11-26-2009 |
20090291128 | TRANSDERMAL DELIVERY OF CANNABINOIDS - The present invention overcomes the problems associated with existing drug delivery systems by delivering cannabinoids transdermally. Preferably, the cannabinoids are delivered via an occlusive body (i.e., a patch) to alleviate harmful side effects and avoid gastrointestinal (first-pass) metabolism of the drug by the patient. A first aspect of the invention provides a method for relieving symptoms associated with illness or associated with the treatment of illness in a mammalian subject, comprising the steps of selecting at least one cannabinoid from the group consisting of cannabinol, cannabidiol, nabilone, levonantradol, (−)-HU-210, (+)-HU-210, 11-hydroxy-Δ | 11-26-2009 |
20090297591 | Compositions And Methods For The Transdermal Delivery Of Pharmaceutical Compounds - The present invention is directed to compositions and methods for the transdermal delivery of a pharmaceutically active compound. In some embodiments, the addition of inert pharmaceutical ingredients in place of a portion of adhesive in a transdermal patch formulation increases the rate of skin permeation of a pharmaceutical compound. | 12-03-2009 |
20090311311 | TRANSDERMAL LOCAL ANESTHETIC PATCH WITH INJECTION PORT - Described herein are transdermal delivery devices composed of at least one re-sealable injection port and at least one local anesthetic reservoir. The device effectively delivers anesthetic to the skin of the subject prior to puncturing the skin by syringes, needle sticks, or other instruments intended to be inserted into the skin. In addition, this device can be used to deliver various therapeutic agents for either locally or systemically. | 12-17-2009 |
20090311312 | Transdermal Hormone Delivery System: Compositions And Methods - A transdermal hormone delivery system (THDS) is disclosed. The THDS is useful for control of fertility and as therapy for a variety of diseases and conditions treatable by robust delivery of progestin and estrogen hormones, particularly the progestin, levonorgestrel. The THDS comprises a backing layer, an adjoining adhesive polymer matrix comprising an effective amount of at least a progestin hormone, delivery of which is enhanced by one or more skin permeation enhancing agents present in pre-determined amounts. The THDS is capable of providing effective daily doses of progestin and estrogen hormones from a small surface area in contact with the skin, e.g., less than 20 square centimeters. Methods of fertility control and various types of hormone replacement therapy utilizing the THDS are also disclosed. | 12-17-2009 |
20090317452 | Transdermal patch - The present invention provides a transdermal patch having excellent preservation stability and transdermal absorbency of DMAE or its pharmacologically acceptable salt. The patch has a support and a plaster layer integrally laminated on one surface of the support, and the plaster layer includes: 2-amino-1-(2′,5′-dimethoxyphenyl)ethanol or its pharmacologically acceptable salt; 40 to 98% by weight of acrylic adhesive prepared by copolymerizing monomers respectively containing 30 to 99% by weight of alkyl methacrylate having an alkyl group with a carbon number of 6 to 22 and 1 to 70% by weight of alkyl acrylate having an alkyl group with a carbon number of 2 to 20; and 1 to 30% by weight of saturated aliphatic monohydric alcohol having an alkyl group with a carbon number of 10 to 30. | 12-24-2009 |
20090317453 | TRANSDERMAL AND TOPICAL ADMINISTRATION OF DRUGS USING BASIC PERMEATION ENHANCERS - Methods are provided for enhancing the permeability of skin or mucosal tissue to topical or transdermal application of pharmacologically or cosmeceutically active agents. The methods entail the use of a base in order to increase the flux of the active agent through a body surface while minimizing the likelihood of skin damage, irritation or sensitization. The permeation enhancer can be an inorganic or organic base. Compositions and transdermal systems are also described. | 12-24-2009 |
20090317454 | Body or plant part dressing - A dressing having a flexible sleeve shaped to accommodate a substantially cylindrical body or plant portion, the sleeve having a lining which is substantially non-adherent to the body or plant part being bandaged and having a peripheral securement means which attaches two peripheral portions to each other without those portions being circumferentially adhered to the sleeve portion. | 12-24-2009 |
20090324697 | TRANSDERMAL HORMONE DELIVERY SYSTEM: COMPOSITIONS AND METHODS - A transdermal hormone delivery system (THDS) is disclosed. The THDS is useful for control of fertility and as therapy for a variety of diseases and conditions treatable by robust delivery of progestin and estrogen hormones, particularly the progestin, levonorgestrel. The THDS comprises a backing layer, an adjoining adhesive polymer matrix comprising an effective amount of at least a progestin hormone, delivery of which is enhanced by one or more skin permeation enhancing agents present in pre-determined amounts. The THDS is capable of providing effective daily doses of progestin and estrogen hormones from a small surface area in contact with the skin, e.g., less than 20 square centimeters. Methods of fertility control and various types of hormone replacement therapy utilizing the THDS are also disclosed. | 12-31-2009 |
20100003313 | ADHESIVE SKIN PATCH - A plaster including a backing layer and a drug layer laminated on the backing layer, where the drug layer contains an adhesive base and at least one compound selected from the group consisting of citalopram and pharmaceutically acceptable salts thereof, an abundance ratio of the S form being greater than an abundance ratio of the R form. | 01-07-2010 |
20100008974 | TRANSDERMAL GRANISETRON - Adhesive patches for the transdermal administration of granisetron, comprise an acrylic adhesive containing non-acidic nucleophilic moieties which substantially increase flux of granisetron across the skin. | 01-14-2010 |
20100021529 | STEP-DOWN ESTROGEN REGIMEN FOR WOMEN RECEIVING ESTROGEN THERAPY - The present invention relates to methods for continuous treatment of diseases, conditions and/or symptoms associated with deficient endogenous levels of estrogen in a woman already receiving a therapeutically effective dose of an estrogen. More particularly, the present invention provides a safe and efficient step-down regimen for women already receiving estrogen therapy and which are potentially overdosed. | 01-28-2010 |
20100021530 | ENHANCED TRANS-KERATIN DRUG DELIVERY - The teachings provided herein are directed to a system and method for delivering an anti-infective agent through the nail of a subject having a nail infection. The system can comprise a drug delivery mechanism comprising an anti-infective agent and a heating element and a holding mechanism for releasably attaching the drug delivery mechanism to the digit having the infected nail. The drug delivery mechanism does not comprise a nail-infection-agent-containing member or sponge for receiving and delivering the anti-infective agent to the infected nail. In addition, the holding mechanism comprises a substantially open structure that covers the infected nail and does not enclose the digit. The system facilitates an enhanced trans-keratin drug delivery of the anti-infective agent through the infected nail in a dark, warm, and moist environment that prevents the growth of fungi in the infected nail. The teachings also include a heatable bandage for treating an infected nail. | 01-28-2010 |
20100028412 | TRANSDERMAL THERAPEUTIC SYSTEM FOR ADMINISTERING WATER-SOLUABLE ACTIVE INGREDIENTS - The invention relates to a transdermal therapeutic system for the controlled release of water-soluble pharmaceutical active ingredients from an aqueous phase, comprising an occlusive back layer, a central device facing the skin for releasing the agent, an adhesive layer concentrically surrounding the dispensing device and a removable protective film. Said device is made from a stationary solid phase and a liquid phase containing the active ingredient in aqueous solution, the solid phase being formed from a solid with a fleecy or spongy structure. | 02-04-2010 |
20100028413 | SKIN TREATMENT STRIP - The skin treatment strip includes a base liner and an applicant liner coupled to the base liner by an adhesive. The skin treatment strip further includes a chemical layer sandwiched between the base liner and the applicant liner that is reactive to a skin blemish. The chemical layer includes a weak acid such as hydrogen peroxide for treating the skin blemish, a base such as sodium hydroxide for balancing skin pH and preventing skin irritation, a sugar-based alcohol such as glycerin for soothing the skin and a water-based carrier. Preferably, the adhesive is used to maintain contact of the chemical layer with the skin blemish upon application of the applicant liner. | 02-04-2010 |
20100047326 | Multiple-Compartment Applicator - A multiple-compartment ascorbic acid delivery unit is provided. The first compartment is impermeable to oxygen and ultraviolet light and contains a solid vitamin-containing composition comprising ascorbic acid or its pharmaceutically acceptable salts and esters. The second compartment is liquid impermeable and contains a pharmaceutically acceptable carrier system. The first compartment is entirely enclosed within said second compartment or vice versa. An opening is formed in the inner compartment in order to combine the contents of the two compartments to form an ascorbic acid carrier composition prior to delivery to the patient. | 02-25-2010 |
20100047327 | Adjuvant for Transdermal or Transmucosal Administration and Pharmaceutical Preparation Containing the Same - It is intended to provide a low molecular weight adjuvant which can be administered safely without inducing skin irritation or the like by transdermal or transmucosal administration and is for enhancing immunogenicity of an antigen efficiently. It can be achieved by an immunostimulant adjuvant containing at least one substance selected from the group consisting of aliphatic alcohols, free fatty acids and fatty acid derivatives but does not contain a substance represented by the following formula. | 02-25-2010 |
20100047328 | Adhesive preparation - An adhesive preparation comprising a stretchable support and an adhesive layer laminated on at least one side of the support, wherein
| 02-25-2010 |
20100055161 | HYDROGEL FACE MASK FOR DELIVERING SKIN CARE AGENTS - Skin care can be provided by the skin care devices and compositions described herein. Such a skin care device can be configured to include a biocompatible hydrogel layer including one or more treatment agents, and an associated backing layer associated with the hydrogel layer. | 03-04-2010 |
20100055162 | ADHESIVE PATCH - An adhesive patch having a support | 03-04-2010 |
20100062046 | POLYMORPHS OF NICOTINIC INTERMEDIATES - Crystalline forms of compounds (II), (III) and (IV) and processes to produce them are provided. | 03-11-2010 |
20100068250 | Abuse Potential Reduction in Abusable Substance Dosage Form - The potential for substance abuse involving residual amounts of abusable substances remaining in used skin-worn patches is reduced by the provision of a system and method for combining the abusable substance with a separate anti-abuse substance agent as part of a removal or disposal procedure. | 03-18-2010 |
20100074944 | Transdermal Tobacco Alkaloid Reservoir Patch - The invention relates to a tobacco alkaloid patch ( | 03-25-2010 |
20100086581 | METHOD FOR PURPURA REDUCTION AND PREVENTION - A method for reducing or eliminating skin discoloration caused by purpura or similar conditions uses corticosteroids, particularly glucocorticoids, in a long term cutaneous treatment. A cream, ointment, spray or other means is used to apply a glucocorticoid, for example, hydrocortisone to warmed skin having a red or purple discoloration. Application is continued daily for several months or years to reduce, eliminate and prevent discoloration. | 04-08-2010 |
20100086582 | AMORPHOUS ROTIGOTINE TRANSDERMAL SYSTEM - The present invention refers to a transdermal delivery device comprising a backing layer, an adhesive matrix layer comprising a supersaturated concentration of rotigotine substantially in amorphous form within the adhesive matrix, and a release liner. The present invention also refers to a method of preparing an adhesive matrix containing a supersaturated amount of rotigotine substantially in amorphous form. Further, the present invention refers to a method of stabilizing and a method of reestablishing the meta-stable amorphous-drug transdermal system during its manufacturing, storing, shipping and handling process. | 04-08-2010 |
20100092546 | Topical and Transdermal Delivery of HIF-1 Modulators to Prevent and Treat Chronic Wounds - Compositions and methods are provided for the treatment of chronic wounds, including, without limitation, pressure ulcers and diabetic ulcers, by transdermal delivery of an agent that increases activity of HIF-1α in the wound. Agents that increase HIF-1α activity include, without limitation, agents that stabilize HIF-1α, e.g. deferoxamine, deferiprone, deferasirox, etc.; agents that upregulate expression of HIF-1α, e.g. dimethyloxalylglycine, etc., HIF-1α polypeptide or coding sequences; and combinations thereof. Such agents may be referred to herein as HIF-1α potentiating agents. | 04-15-2010 |
20100098747 | PERCUTANEOUS ADMINISTRATION DEVICE OF BISOPROLOL - The present invention relates to a percutaneous administration device of bisoprolol, which includes a backing; and a pressure-sensitive adhesive layer containing bisoprolol, which is laminated on one surface of the backing, wherein the maximum value of a release rate of bisoprolol during a period of from immediately after the application on skin until a lapse of 24 hours is 30 μg/cm | 04-22-2010 |
20100104621 | TREATING ADHD AND OTHER DISEASES INVOLVING INFLAMMATION - The present disclosure relates to methods and drug delivery systems for treating diseases involving inflammation, including Attention Deficit Hyperactivity Disorder (ADHD) by administering a CNS stimulant to a patient in need thereof so as to maintain steady state serum drug levels that remain therapeutically effective for about 24 and ½ to about 25-27 hours or longer after administration to maintain a constant steady state between doses of medication. The method is employed to restore normal catecholamine levels throughout the day without over-stimulating or under-stimulating the patient. Additionally, the present method of treating inflamτnaτion3 including ADHD, provides, for example, dosing once a day or once a week. The present method also addresses other aspects of the disease, for example, defective P-5-P synthesis, ehminating interleukins and free radicals, and correction of Amino acids, the endocrine system and inflammation. The present systems and methods heal the brain, treat depression and ADHD, and may lower the amount of medication needed over time. | 04-29-2010 |
20100112037 | S1P RECEPTOR AGONISTS FOR THE TREATMENT OF CEREBRAL MALARIA - Methods and compositions for treating, managing, and/or preventing cerebral malaria are disclosed. | 05-06-2010 |
20100119585 | TRANSDERMAL THERAPEUTIC SYSTEM FOR ADMINISTERING THE ACTIVE SUBSTANCE BUPRENORPHINE - The invention relates to a transdermal therapeutic system for administering the active substance buprenorphine. Said system comprises at least one carboxylic acid that determines the solubility of buprenorphine in the matrix layer and that can likewise be absorbed. The transdermal therapeutic system according to the invention is used in the treatment of pain and is characterized by a considerably increased utilization of the active substance. | 05-13-2010 |
20100119586 | Patch for Cutaneous Application - The invention relates to a patch for cutaneous application of a substance, the patch comprising a substance designed to penetrate the epidermis, means for placing the substance in contact with the skin and a peelable cutaneous exfoliation film enabling exfoliation of the skin, after placing the patch, at the level of the contact zone between said substance and the skin. | 05-13-2010 |
20100136092 | TRANSDERMAL IMMUNE PREPARATION, METHOD FOR PRODUCTION OF THE SAME, AND TRANSDERMAL IMMUNIZATION METHOD USING THE SAME - This invention is concerned with transdermal immune preparations which can exhibit a high immunological activity without containing any adjuvant, methods for producing the preparation, and transdermal immunization methods using the preparation. | 06-03-2010 |
20100136093 | Immunotherapeutic Method For Increasing Groundnut Tolerance In A Subject - The present invention describes a new method for progressive desensitization of a subject to groundnut. More specifically, the invention relates to the immunotherapeutic method for increasing groundnut tolerance in an allergic subject using epicutaneous administration. The present invention is also relative to the use of a skin patch device for progressive desensitization of a subject to groundnut. | 06-03-2010 |
20100143448 | MULTIPLE NOZZLE TRANSDERMAL DRUG DELIVERY SYSTEM - A transdermal drug delivery system ( | 06-10-2010 |
20100150993 | TRANSDERMAL THERAPEUTIC SYSTEM COMPRISING NORELESTROMIN FOR CONTRACEPTION AND HORMONE REPLACEMENT - The present invention relates to a transdermal therapeutic system for applying the active ingredient norelgestromin onto the skin, optionally in combination with estrogens. It further relates to the use of such systems for hormonal contraception, and for hormone replacement therapy. | 06-17-2010 |
20100150994 | AMPHIPHILIC ENTITY NANOPARTICLES - The present invention provides nanoparticle compositions comprising AE nanoparticles. The present invention provides AE nanoparticles comprising one or more amphiphilic entities and pharmaceutical compositions comprising AE nanoparticles. The present invention provides methods of manufacturing AE nanoparticles. The present invention provides methods of delivering a biologically active agent to a subject by administering AE nanoparticles containing a biologically active agent to a subject. | 06-17-2010 |
20100150995 | PROCESS FOR THE PRODUCTION OF HIGH-PURITY 2,4'-DIMETHYL-3-PIPERIDINO-PROPIOPHENONE (TOLPERISONE), PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THE LATTER, AS WELL AS ACTIVE INGREDIENT FORMULATIONS THAT CONTAIN TOLPERISONE - The invention relates to a method for producing highly pure 2,4′-dimethyl-3-piperidino-propiophenone (tolperisone) (formula I) and the pharmaceutically acceptable salts, hydrochlorides, and hydrates thereof. The method allows the content of the undesired byproduct 2-methyl-1-(4-methylphenyl) propenone (4-MMPPO) to be kept significantly lower than in previously known methods. The invention further relates to active substance formulations which contain tolperisone and are suitable, among other things, for producing combination preparations used for treating patients suffering from Alzheimer's disease. The invention also relates to topical formulations, controlled release (CR) formulations, and transdermal therapeutic systems, such as active substance patches, which contain less than 50 ppm, preferably less than 10 ppm, more preferably less than 7 ppm, and most preferably less than 3 ppm or 0 ppm (i.e. less than the detectable amount) of the undesired byproduct 2-methyl-1-(4-methylphenyl) propenone (4-MMPPO) in relation to 100 percent by weight of active substance. | 06-17-2010 |
20100150996 | ATHLETIC PATCH - The present invention relates to patches for the administration of an athletic supplement to subjects engaged in rigorous exercise or heavy outdoor work. The invention also relates to methods of administering nutrients to subjects using the patch of the invention. | 06-17-2010 |
20100166837 | 1,(3,)5-SUBSTITUTED IMIDAZOLES, THEIR USE IN THE TREATMENT OF HYPERTENSION AND METHODS FOR THEIR PREPARATION - The present invention provides novel 1,5 and 1,3,5-substituted imidazole compounds in hydrophilic or lipophilic form, which are useful as angiotensin II ATI receptor antagonists suitable for transdermal delivery. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing compounds and their use in methods of treating hypertension and cardiovascular diseases. | 07-01-2010 |
20100172959 | RESERVOIR SYSTEM WITH CLOSED MEMBRANE - A dermal or transdermal therapeutic system comprising a reservoir that contains at least one active substance, an active substance-permeable membrane which delimits the active-substance reservoir, and a closing layer. The closing layer is impermeable to the active substance at a temperature lying below the skin temperature while being permeable at skin temperature and above. | 07-08-2010 |
20100172960 | PRO-DRUGS OF NSAIAS WITH VERY HIGH SKIN AND MEMBRANES PENETRATION RATES AND THEIR NEW MEDICINAL USES - The novel positively charged pro-drugs of NSAIAs in the general formulas (1, 2a, 2b, 2c, or 2d) “Structure 1, 2a, 2b, 2c, or 2d” were designed and synthesized. The compounds of the general formulas (1, 2a, 2b, 2c, or 2d) “Structure 1, 2a, 2b, 2c, or 2d” indicated above can be prepared from metal salts, organic base salts, or immobilized base salts of NSAIAs with suitable halide compounds. The positively charged amino groups in the pro-drugs in this invention largely increase the solubility of the drugs in water and will bond to the negative charge on the phosphate head group of membrane. Thus, the local concentration of the outside of the membrane or skin will be very high and will facilitate the passage of these pro-drugs from a region of high concentration to a region of low concentration. This bonding will disturb the membrane a little bit and may make some room for the lipophilic portion of the pro-drug. When the molecules of membrane move, the membrane may “crack” a little bit due to the bonding of the pro-drug. This will let the pro-drug insert into the membrane. At pH 7.4, only about 99% of the amino group is protonated. When the amino group is not protonated, the bonding between the amino group of the pro-drug and the phosphate head group of the membrane will disassociate, and the pro-drug will enter the membrane completely. When the amino group of the pro-drug flips to the other side of the membrane and thus becomes protonated, then the pro-drug is pulled into the cytosol, a semi-liquid concentrated aqueous solution or suspension. These pro-drugs can be used for treating and preventing diabetes (type I or/and type II), abnormal blood glucose and lipid levels, stroke, heart attack, and other heart and vascular diseases Alzheimer's diseases, Parkinson's diseases and other neurodegenerative diseases, psoriasis, discoid lupus erythematosus, systemic lupus erythematosus (SLE), autoimmune hepatitis, multiple sclerosis (MS), and other autoimmune diseases, amyotrophic lateral sclerosis (ALS), oculopharyngeal muscular dystrophy (OPMD), and other muscle disorders, inflamed hemorrhoids, cryptitis, other inflammatory conditions of the anorectum, and pruritus ani, prostatitis, prostatocystitis, varicose veins, autoimmune liver inflammation, autoimmune kidney inflammation, vein inflammation and other inflammations, skin cancers, breast cancer, colon-rectum cancer, oral cancer, and other cancers, scars, abnormal vascular skin lesions, birthmarks, moles (nevi), skin tags, aging spots (liver spots), and other skin disorders. These pro-drugs can be administered transdermally without the help of skin penetration enhancers. | 07-08-2010 |
20100196449 | SYSTEM AND METHOD TO IMPROVE SENSORY FUNCTION - A system and method to improve sensory functions in the hand or foot by dermal topical application of a local anaesthetic substance to adjacent skin areas, using a tailored application device or kit specially designed to fit the size and anatomical shape of the body part which is to be anaesthetised. The concept is to block sensory input from the anaesthetised skin area hereby inducing a functional reorganisation in sensory brain cortex resulting in enhanced sensory functions in body parts adjacent to the anaesthetised area with focus on the hand and sole of the foot. | 08-05-2010 |
20100209484 | Transdermal Triptan Delivery System - This invention relates to transdermal system for the systemic administration of an active ingredient such as a triptan selected from the group comprising eletriptan, frovatriptan, sumatriptan, zolmitriptan, naratriptan, rizatriptan and almotriptan uniformly over periods of 12 to 24 hours or more thereby reducing the probability of recurring migraine. The formulation includes active ingredient, adhesive matrix and permeation enhancer. The invention also relates to storage stable formulations and methods for preventing migraine and cessation of an ongoing migraine event. | 08-19-2010 |
20100221314 | Microneedle Device - A microneedle device having a coating including a high molecular weight pharmaceutical compound substantially uniformly is provided. | 09-02-2010 |
20100226966 | Method for transdermal controlled release drug delivery - Provided herein are dosing methods for administering a biologically active agent using microprojections and microprojection arrays. The microprojections may be coated with at least two layers in order to achieve sustained release of the agent into a patient's blood stream. One layer comprises a biologically active agent, for example, a PTH agent and optionally other excipients. Another layer, which is generally, initially devoid of active agent comprises a polymer or a mix of polymers to provide controlled release, for example sustained release, of the biologically active agent contained in the first layer. Microprojections coated with multiple layers, some layers containing a biologically active agent and other layers containing a polymer for controlled release are also contemplated herein. | 09-09-2010 |
20100239646 | Sublingual methotrexate and methotrexate patches - Several major new inflammatory diseases that respond to methotrexate are identified in this Invention. These newly identified indications that respond to methotrexate include a number of cardiovascular diseases, coronary heart disease and stroke. To optimize and improve therapeutic effectiveness, therapeutic responses and to minimize toxicity new sublingual dosage units and patches of methotrexate are taught in this Invention for direct delivery of the drug to the blood stream bypassing absorption through the human gut. The practice of this invention as provided herein should result in significant improvement of the therapeutic index of methotrexate in the treatment of a number of painful, crippling, disfiguring, and fatal diseases. This Invention therefore addresses an unmet need to treat the above diseases for which there are no curative treatments are available at the present time. The use of sublingual methotrexate or methotrexate patches to prevent, treat or reverse cardiovascular diseases, coronary heart disease and stroke is new and the practice of this invention should result in very significant therapeutic improvements and commercial benefits. | 09-23-2010 |
20100239647 | PHOTORESPONSIVE IONOGEL - A photoresponsive ionogel comprising a photo-responsive polymer polymerised within an ionic liquid matrix is described. This solid-state electrolyte material maintains its ionic liquid characteristics but these characteristics can be altered upon irradiation of the gel with light of a particular wavelength. By suitably configuring the ionogel through the incorporation of specific ions within the gel it is possible to cause dramatic changes in properties of the ionogel such as viscosity, conductivity, acidity, basicity and polarity using light as the stimulus. | 09-23-2010 |
20100239648 | SELF-LOCATING, MULTIPLE APPLICATION, AND MULTIPLE LOCATION MEDICAL PATCH SYSTEMS AND METHODS THEREFOR - A medical patch system has a first medical patch including an outer locating ring secureable to a surface and an inner patch, separable from the outer locating ring, disposed within the outer locating ring. The medical patch system includes a second medical patch adapted for insertion into the central area bounded by the outer locating ring after the inner patch is separated from the outer locating ring. The second medical patch includes a second outer locating ring secureable to the surface, and a second inner patch section, separable from the second outer locating ring, disposed within a second central area bounded by the second outer locating ring. The first and second outer locating rings have adhesive layers for securing the outer locating rings to a surface. The adhesive layers on the respective outer locating rings have different sizes, shapes or patterns to minimize skin irritation. | 09-23-2010 |
20100247617 | Transdermal Administration Of (2S)-(4E)-N-Methyl-5-(3-(5-Isopropoxypyridin)yl)-4-Penten-2-Amine - The present invention generally relates to the transdermal administration of (2S)-(4E)-N-methyl-5-(3-(5-isopropoxypyridin)yl)-4-penten-2-amine, or pharmaceutically acceptable salts thereof. The transdermal administration can be effected using transdermal drug delivery devices, semi-solid dosage forms, or iontophoresis. The drug delivery devices and/or semi-solid dosage forms can provide instantaneous release, sustained release, or combinations thereof, and can include permeation enhancers and other components to assist in drug transport across the dermis, especially the epidermis. The compositions can be used to treat and/or prevent any indication which the active ingredients are capable of treating and preventing, but deliver (2S)-(4E)-N-methyl-5-(3-(5-isopropoxypyridin)yl)-4-penten-2-amine, or pharmaceutically acceptable salts thereof, in an efficacious manner. Disorders that can be treated and/or prevented include central nervous system disorders, addictions, pain, and inflammation. | 09-30-2010 |
20100255071 | Patch and patch preparation - Provided are a patch and a patch preparation having an adhesive layer on at least one surface of a support, and particularly, a patch and a patch preparation superior in skin adhesive force, and causing less adhesive residue on the skin surface. A patch having a support and an adhesive layer formed on at least one surface of the support, wherein the adhesive layer contains an elastomer obtained by crosslinking a polymer having a butadiene skeleton in the presence of an organic peroxide, and the ratio of the weight of a toluene-insoluble component in the adhesive layer to the total weight of the adhesive layer is 5-32 wt %. | 10-07-2010 |
20100255072 | DERMAL DELIVERY DEVICE WITH IN SITU SEAL - This invention relates to a transdermal drug delivery device that comprises an active ingredient (Al) layer, having a skin contacting surface and a non-skin contacting surface and comprising a volatile component, a release liner impermeable to the volatile component adjacent the skin contacting surface of the Al layer having a peπmeter that extends beyond the perimeter of the Al layer in all directions, and an overlay comprising a pressure sensitive adhesive (PSA) that does not absorb the volatile component adjacent the non-skin contacting surface of the Al layer having a peπmeter of which extends beyond the penmeter of the Al layer in all directions, wherein the release liner and the PSA of the overlay are in contact with and adhered to each other around the peπmeter of the Al layer to form a seal that reduces or prevents volatile component loss. | 10-07-2010 |
20100255073 | COMPOSITION FOR TRANSDERMAL DELIVERY OF FENTANYL - A transdermal drug delivery composition comprises an acrylate copolymer and from about 8% to about 30% by weight fentanyl. A transdermal fentanyl delivery composition comprising methyl laurate or tetraglycol as a permeation enhancer is also provided. The transdermal drug delivery compositions can be used to make a transdermal drug delivery device for the delivery of fentanyl. | 10-07-2010 |
20100260825 | Antifolates for the treatment of cardiovascular, inflammatory, neoplastic, autoimmune and related diseases in sublingual dosage units, film strips, or skin patches - New metabolism blocked antifolates and their salts are provided along with new indications (coronary heart disease, cardiovascular diseases, stroke and termination of tubal or ectopic pregnancy) and methods (sublingual dosage forms, filmstrips or patches) for their use and delivery. Sublingual dosage forms or trans-dermal patches of metabolically blocked entities of this invention offer superior alternatives to traditional oral dosage forms to achieve greater and predictable therapeutic efficacy, lower toxicity and to overcome drug resistance by virtue of elimination of oxidative deactivation and production of toxic metabolites. Metabolism blocked antifolates bearing a fluorinated benzene ring, a thiophene ring, a pyrrole ring, a furan ring or a 8-deazapteridine ring that are provided in this invention are not previously described. The use of metabolism blocked antifolates to terminate medically complicated pregnancies that are taught herein are new inventions targeted to eliminate drug related toxicity to the host and to enhance therapeutic efficacy. | 10-14-2010 |
20100260826 | Patch and patch preparation - Provided are a patch and a patch preparation having an adhesive layer on at least one surface of a support, and particularly, a patch and a patch preparation superior in skin adhesive force, and causing less adhesive residue on the skin surface. A patch having a support and an adhesive layer formed on at least one surface of the support, wherein the adhesive layer is obtained by crosslinking a first polymer having a butadiene skeleton portion and a second polymer different from the first polymer in the presence of an organic peroxide. | 10-14-2010 |
20100266671 | Device and Method for Treating Dermal Tissue - The present disclosure provides gel compositions useful for treating the skin. The gel compositions are hydrogels that include from about 33 wt % to about 68 wt % of a humectant or a mixture of humectants; about 0 wt % to about 8 wt % of an electrolyte or mixture of electrolytes; from about 2 wt % to about 20 wt % of water; from about 18 wt % to about 45 wt % of a copolymer. The copolymer includes, in polymerized form, from about 80 mol % to about 95 mol % of a first monomer, which is a mixture of acrylic acid and a salt thereof, from about 5 mol % to 20 mol % of a second monomer, which can be a salt of 2-acrylamido-2-methylpropane sulfonic acid, and, optionally a crosslinking agent. In embodiments, the gel composition has a pH of about 7.0 or less. The dermal patches of the present disclosure may be utilized in skin care, and may include the application of the patch, its removal, and re-application to tissue. | 10-21-2010 |
20100291186 | Transdermal Administration of Tamsulosin - In an aspect of the invention, a composition for making a patch for the transdermal delivery of tamsulosin is provided. The composition comprises (a) at least about 1 wt % tamsulosin or a pharmaceutically acceptable salt of tamsulosin, (b) at least about 40 wt % polyisobutylene adhesive or hydrophobic synthetic rubber adhesive, (c) about 1-20 wt % of an aprotic solvent in which tamsulosin dissolves readily, (d) about 1-20 wt % of an unsaturated fatty acid or an alpha-hydroxy acid or a mixture of unsaturated fatty acids or alpha-hydroxy acids or of both unsaturated fatty acids and alpha-hydroxy acids, (e) a lipophilic permeation enhancer, and (f) a matrix modifier. | 11-18-2010 |
20100291187 | Adhesive laminates for rapid wound occlusion - Provided herein are protective laminate devices comprising a biocompatible non-adherent substance and a fast-setting adhesive and methods of use. Also provided is a dispenser for an adhesive tape. The protective laminate devices and methods may be used for wound closure. | 11-18-2010 |
20100303892 | TRANSDERMAL THERAPEUTIC SYSTEM CONTAINING ELONGATE HOLLOW BODIES - The invention relates to a transdermal therapeutic system for applying an active ingredient or several active ingredients to the skin. Elongate hollow bodies are incorporated into one of the layers of the TTS, said hollow bodies containing a filling medium or several filling mediums. The invention also relates to the production and use of said type of systems. | 12-02-2010 |
20100310634 | TRANSDERMAL THERAPEUTIC SYSTEM HAVING UREA COMPONENTS - The invention relates to a transdermal therapeutic system (TTS) for administering pharmaceutical agents through the skin, comprising a back layer (R) impermeable to the agent and at least one layer (S) comprising the agent, wherein the layer (H) facing the skin comprises urea in solid form, allowing continuous administration of large quantities of agent over a long period of time. | 12-09-2010 |
20100316695 | CONDENSATION PRODUCTS BASED ON BICYCLIC OR POLYCYCLIC AROMATICS OR HETEROAROMATICS - The invention relates to a condensation product obtainable by reaction of
| 12-16-2010 |
20100322999 | FENTANYL-CONTAINING PATCH FOR EXTERNAL USE - A patch for external use which has a laminate structure comprising a substrate and a pressure-sensitive adhesive layer which contains a styrene/isoprene/styrene block copolymer as the base and further contains a tackifier resin consisting of a rosin resin and at least one other tackifier resin, a softening agent consisting of polybutene and liquid paraffin, a fatty acid ester, and fentanyl, characterized in that the weight ratio of the rosin resin to fentanyl is 1 to 5, the weight ratio of the rosin resin to the whole tackifier resin is 0.1 to 0.6, and the tackifier resin accounts for 30 to 60wt % of the whole pressure-sensitive adhesive layer. The patch is excellent in the permeation of fentanyl through the skin and in storage stability, and is weak in irritation to skin. | 12-23-2010 |
20110020426 | PROCESS FOR THE CONTINUOUS MANUFACTURE OF A POLYISOBUTYLENE BASED TRANSDERMAL PATCH - The present invention is directed to a process for manufacturing a transdermal delivery device comprising a backing layer, a release liner, and an adhesive layer between the backing layer and release liner. More specifically, the invention is directed to a process of preparing an adhesive layer, wherein the adhesive layer is comprised of polyisobutylene and an active pharmaceutical ingredient. | 01-27-2011 |
20110064788 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF ADDICTION - The invention provides transdermal patches comprising an adhesive and a composition comprising naltrexone and either methyl oleate or isopropyl myristate, a kit comprising a plurality of such transdermal patches, a composition comprising naltrexone and methyl oleate, such a composition for use as a medicament, and compositions comprising naltrexone and methyl oleate or isopropyl myristate for use in the treatment of alcoholism or opiate addiction. | 03-17-2011 |
20110086086 | TRANSDERMAL SYSTEM FOR VARENICLINE - The invention provides transdermal compositions comprising varenicline or its pharmaceutically acceptable salt or prodrug form. | 04-14-2011 |
20110104246 | METHOD OF WOUND TREATMENT USING LIQUID GALLIUM NITRATE - A pharmaceutical composition and method for topical wound treatment by topical treatment with gallium salts, preferably gallium nitrate. In a preferred embodiment, the gallium nitrate is in an aqueous form without coagulation inhibitors such as citrate. The aqueous gallium salt formulation may be administered by a variety of methods including spraying, topical lotions, topical foams, and/or bandages containing or packaged with breakable ampoules of aqueous gallium salt formulations, and liquid bandage formulations. The aqueous gallium salt formulation may additionally contain other active and inactive ingredients, such as viscosity modifying agents, foaming agents, antiseptics, antibiotics, enzymes, fibrinogen, fibrin, polymers and growth factors. | 05-05-2011 |
20110104247 | COMPOSITION FOR STABILIZING BETA-BLOCKER AND TRANSDERMALLY ABSORBABLE PREPARATION COMPRISING THE SAME - The present invention relates to a transdermally absorbable composition which is capable of retaining a β-blocker stably for a long period. More specifically, the present invention relates to a transdermally absorbable composition for stabilizing a β-blocker, which comprises a polymer compound having an amino group, a polyvalent carboxylic acid ester, a fatty acid ester and an acrylic polymer compound. | 05-05-2011 |
20110111013 | TRANSDERMAL THERAPEUTIC SYSTEM FOR ADMINISTRATION OF FENTANYL OR AN ANALOGUE THEREOF - What is disclosed is a transdermal therapeutic system for administration of an active ingredient through the skin, comprising: (a) a back layer, (b) a reservoir present on the back layer, comprising the active ingredient, polyisobutylene, a gel former and a plasticizer, a portion of the active ingredient in the reservoir being present in the form of undissolved particles and the content of gel formers in the reservoir being at most 4% by weight (based in the total weight of the reservoir), the active ingredient being Fentanyl or an analogue thereof. | 05-12-2011 |
20110129521 | PHARMACEUTICAL COMPOSITION CONTAINING A HYPOMETHYLATING AGENT AND A HISTONE DEACETYLASE INHIBITOR - A pharmaceutical composition for induction therapy which has a hypomethylating agent and a histone deacetylase inhibitor (“HDAC inhibitor”); wherein the hypomethylating agent is a DNA and histone methylation inhibitor such as cladribine and the HDAC inhibitor is, for example, entinostat, panobinostat, vorinostat, and/or romedepsin; further wherein the hypomethylating agent and the HDAC inhibitor are combined in formulations for various administrations including e.g., a continuous delivery system such as a transdermal patch of at least one reservoir or a plurality of reservoirs, oral, a fixed-dose oral combination, intravenous, and combinations thereof. This pharmaceutical composition for induction therapy is used with a monoclonal antibody in the treatment of various cancers, sarcomas, and other malignancies. | 06-02-2011 |
20110129522 | TRANSDERMAL SYSTEM FOR EXTENDED DELIVERY OF INCRETINS AND INCRETN MIMETIC PEPTIDES - A transdermal patch formulation of a viscous liquid that includes an active agent of incretin or incretin mimetic peptide, a stabilizer, a buffer, a water soluble thickening agent, and a pharmaceutically acceptable carrier. Also, a patch adapted for transdermal delivery of the active agent and having a drug reservoir compartment of the transdermal patch formulation and a system for facilitating transdermal delivery of the active agent through the skin of a subject. The system includes the patch and an apparatus capable of generating a plurality of micro-channels in an area on the subject's skin. The patch and apparatus are used in methods of treatment for reducing blood glucose level, lowering plasma glucagon levels, reducing food intake, or reducing gastric motility in a subject in need of the same by extending the release of the incretin or incretin mimetic peptide in the subject. | 06-02-2011 |
20110150975 | Treatment of Mammalian Physiological Reaction of IgE Antibodies Present in Said Mammal Upon Contact With the Corresponding Antigen - A method is disclosed for blocking or reducing physiological reaction in a mammal to the interaction of IgE antibodies present in said mammal upon contact with the corresponding antigen, by the administration to said mammal of a therapeutically effective amount of a neurotoxin (CnT) derived from Clostridia sp. | 06-23-2011 |
20110150976 | TRANSDERMAL DELIVERY OF OLIGOSACCHARIDES - The present invention relates to a system for facilitating transdermal delivery of oligosaccharides, The system includes an apparatus that generates micro-channels in the skin of a subject and a skin patch. The patch includes a pharmaceutical composition containing an active agent of an oligosaccharide. Particularly, the oligosaccharide has 5 to 20 monosaccharide units, such as a pentasaccharide, which exerts anticoagulant activity. The system is capable of delivering the oligosaccharides into the blood circulation for treating thromboembolic diseases. | 06-23-2011 |
20110182972 | LOW-CONCENTRATION CAPSAICIN PATCH AND METHODS FOR TREATING NEUROPATHIC PAIN - Described here are patches and methods for treating neuropathic pain. In some variations, the neuropathic pain-relieving patch comprises capsaicin or a capsaicin analog, wherein the concentration of the capsaicin or capsaicin analog is less than 1% by weight, and a penetration enhancer, wherein the patch is capable of relieving neuropathic pain over a sustained period of time. The penetration enhancer may be any suitable penetration enhancer. The patches may also include oils, viscosity increasing agents, and the like. In some variations, the pain-relieving patches comprise capsaicin, or an, wherein the concentration of the capsaicin or analog is less than 1%, and a penetration enhancer, whereby delivery of capsaicin from the patch continues for at least an hour, and whereby a single use of the patch provides a therapeutic benefit for at least one month, two months, or three months. Methods for treating neuropathic pain are also described. | 07-28-2011 |
20110200663 | Methylphenidate patch preparation - Provided is a methylphenidate patch preparation superior in the stability of a drug (methylphenidate and/or a salt thereof) in the patch preparation, skin permeability of a drug during use of the patch preparation, and methylphenidate availability. A patch preparation having a support and an adhesive layer formed on at least one surface of the support, wherein the adhesive layer contains methylphenidate and/or a salt thereof, polyisobutylene and a liquid plasticizer. The liquid plasticizer preferably has an HLB value of 1.0-3.3. | 08-18-2011 |
20110223237 | SELEGILINE-CONTAINING ADHESIVE PREPARATION - The present invention provides an adhesive preparation, which includes a backing and a pressure-sensitive adhesive layer formed on at least one side of the backing, the pressure-sensitive adhesive layer containing (−)-(R)—N,α-dimethyl-N-2-propynylphenethylamine and/or a pharmaceutically acceptable salt thereof, a pressure-sensitive adhesive, an antioxidant and a metal hydroxide. | 09-15-2011 |
20110244023 | TRANSDERMAL DELIVERY PATCH - A composition suitable for use in a transdermal delivery patch for administration of a biologically active compound, the composition comprising a phosphate compound of tocopherol and a polymer carrier. | 10-06-2011 |
20110256211 | Transdermal Delivery - Dosing regimen for transdermal delivery of hormones comprising a 28 day treatment cycle with a fixed treatment interval and a fixed rest interval. | 10-20-2011 |
20110268786 | PATCH PRODUCTION TECHNOLOGY - The invention relates to a transdermal, especially dopaminergic patch, comprising a release liner film, an active substance layer, and a carrier film, wherein the active substance layer is applied between the release liner film and the carrier film. The release liner film and/or the carrier film thereby comprise at least one separation edge brought about thermally, at least partially defining a peripheral edge of the patch. The invention further relates to a method for producing such a transdermal patch and to a tool for producing the patch according to the method according to the invention. Crystal growth in the active substance layer can be reliably prevented by the patch according to the invention. | 11-03-2011 |
20110305746 | PATCH FOR TREATING CONSTIPATION USING CRUDE DRUGS - The present invention relates to a patch for treating constipation, which contains rhubarb ingredients selected from among crude drugs (medical herbs). More particularly, the present invention relates to a patch for treating constipation in which powder obtained by boiling, filtering, and free-drying rhubarb selected from among pure crude drugs is applied to the patch, and the patch is attached to the recesses (arched parts) below the wrists of both hands of a patient, to thereby increase the metabolism of internal organs of the patient and exhibit the effects of treating or preventing constipation. The patch of the present invention can be simply attached to the skin of the patient instead of directly administering agents for treating constipation to the patient. | 12-15-2011 |
20120034293 | TRANSDERMAL DELIVERY OF CANNABINOIDS - The present invention overcomes the problems associated with existing drug delivery systems by delivering cannabinoids transdermally. Preferably, the cannabinoids are delivered via an occlusive body (i.e., a patch) to alleviate harmful side effects and avoid gastrointestinal (first-pass) metabolism of the drug by the patient. A first aspect of the invention provides a method for relieving symptoms associated with illness or associated with the treatment of illness in a mammalian subject, comprising the steps of selecting at least one cannabinoid from the group consisting of cannabinol, cannabidiol, nabilone, levonantradol, (−)-HU-210, (+)-HU-210, 11-hydroxy-Δ | 02-09-2012 |
20120064146 | Wound care device - A wound care device for local treatment of pain in a wound, said device comprising an active pain relieving composition, the device being constructed in such a manner that the pain killing agent is released to the wound in such a way that substantially no effective systemic plasma concentration of the pain killing agent can be found and wherein a majority of said pain killing agent is in direct contact with the wound. | 03-15-2012 |
20120156279 | HIGH PENETRATION PRODRUG COMPOSITIONS OF PEPTIDES AND PEPTIDE-RELATED COMPOUNDS - The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) of peptides and peptide-related compounds, which are capable of crossing biological barriers with higher penetration efficiency comparing to their parent drugs. The HPPs are capable of being converted to parent drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs/HPCs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPPs/HPCs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate. | 06-21-2012 |
20120171278 | PERCUTANEOUS ABSORPTION TYPE PLASTER - A transdermal patch comprising a backing | 07-05-2012 |
20120207816 | Transdermally Absorbable Donepezil-Containing Preparation - Provided is a donepezil-containing transdermal absorption formulation that can sustainably administer donepezil for a long period of time, and can provide both a rapid increase in the blood level of donepezil and donepezil sustained release properties. The donepezil-containing transdermal absorption formulation is a transdermal absorption formulation produced by dissolving donepezil, which is the active ingredient, in an adhesive patch base that contains a hydrophobic polymer and an absorption promoter. The absorption promoter is one kind or two or more kinds selected from lauryl alcohol, triethyl citrate, isopropyl myristate, cetyl lactate, oleyl alcohol, sorbitan monooleate, polyethylene glycol monostearate, lauromacrogol, N-methyl-2-pyrrolidone, and triacetin. | 08-16-2012 |
20120225112 | Method and Apparatus for Alcohol Administration - The method and apparatus for the administration of alcohol to a person provides an alcohol “patch” in the form of an adhesive patch or bandage-like structure bearing a quantity of alcohol for transdermal delivery to the user. Permeation enhancers, either chemical or structural, may be included for increased efficacy of delivery of the alcohol to the user. The alcohol to be delivered via the inventive apparatus may be plain ethyl alcohol (ethanol) of any suitable concentration or proof. Alternatively, the alcohol may be in the form of various distilled or undistilled spirits. | 09-06-2012 |
20130122079 | TRANSDERMAL ADHESIVE COMPOSITIONS, DEVICES AND METHODS - A stable transdermal adhesive composition comprising: an adhesive comprising a washed polymerization reaction product of at least two ethylenically unsaturated monomers; and at least one pharmaceutically active compound which is susceptible to oxidative degradation; wherein the at least two ethylenically unsaturated monomers, if present in the adhesive as unreacted monomers, are present at a level of less than 200 ppm of total unreacted monomer, based upon the total weight of the adhesive, methods of making the composition, a transdermal drug delivery device using the composition, methods of making the device, and methods of delivery the pharmaceutically active compound are provided. | 05-16-2013 |
20140030316 | TRANSDERMAL ADMINISTRATION OF FENTANYL AND ANALOGS THEREOF - A method and a non-rate controlled, monolithic, subsaturated patch for transdermally administering fentanyl and analogs thereof, for analgetic purposes, to a subject through skin over an extended period of time are disclosed. | 01-30-2014 |
20140056965 | METHOD AND SYSTEM FOR TREATING DEPRESSION OR EPILEPSY - A removable patch configured to be applied over a skin surface, comprises an adhesive layer disposed on the removable patch, and a delivery layer disposed on the removable patch. The delivery layer carries an activating chemical neuromodulator adapted to be transcutaneously applied to afferent A fibers disposed under the skin surface. The delivery layer further carries an inhibiting chemical neuromodulator adapted to be transcutaneously applied to C fibers disposed under the skin surface. A method for treating a patient suffering from a neurological disorder comprises transcutaneously applying an activating chemical neuromodulator over a skin surface adjacent to a trigeminal nerve tissue of the patient, and activating afferent A fibers in the trigeminal nerve, the activation being carried out by the chemical neuromodulator. | 02-27-2014 |
20140093555 | PATCH PREPARATION CONTAINING AMINE OXIDE - The present invention provides a patch preparation containing a support and an adhesive layer on at least one surface of the support, wherein the adhesive layer contains a drug, amine oxide, a low-polar liquid component based on an organic compound having an angle of 0-19° as calculated by the formula (I): | 04-03-2014 |
20140105959 | METHOD AND DEVICE FOR REDUCING DERMAL FILLER ADVERSE EVENTS - Methods and devices of aesthetically enhancing and improving appearance of aging skin are provided. Methods may include the steps of treating a skin site selected for dermal filler administration with a mechanism effective to enhance drug delivery across the skin, applying to the treated site, a device, compound or formulation including an active agent effective to reduce visible bruising due to administration of a dermal filler into the site, and administering a dermal filler into the skin site thereby reduce the appearance of wrinkles or folds in the skin site without causing significant bruising. Devices for reducing or ameliorating adverse events from dermal filler administration are also included. | 04-17-2014 |
20140134230 | TRANSDERMAL THERAPEUTIC SYSTEM - The present invention relates to Transdermal Therapeutic Systems having a silicone adhesive layer, to Transdermal Therapeutic Systems providing specific plasma concentrations, to their manufacture and use. | 05-15-2014 |
20140170208 | TRANSDERMAL PATCH FORMULATION - A method for preparing a transdermal patch comprising a substrate layer is provided, the method comprising the steps of contacting an active pharmaceutical ingredient with a retaining means to provide a composition, applying the composition obtained in step (a) to a carrier material to form a substrate layer of the transdermal patch, wherein the retaining means remain within the final transdermal patch. | 06-19-2014 |
20140178459 | COMPOSITIONS AND METHODS FOR TRANSDERMAL DELIVERY OF HORMONES AND OTHER MEDICINAL AGENTS - The invention provides transdermal delivery systems, medical kits, and methods for using the transdermal delivery systems and kits for medical applications, such as delivery of contraceptive agents to control fertility. | 06-26-2014 |
20140220104 | PATCH CONTAINING RIVASTIGMINE - The present invention relates to a rivastigmine-containing patch having improved storage stability and proper release property. | 08-07-2014 |
20140220105 | TAPE PREPARATION OF WT1 PEPTIDE CANCER VACCINE FOR TRANSDERMAL ADMINISTRATION - The present invention provides a cancer vaccine tape preparation for inducing cellular immunity, comprising:
| 08-07-2014 |
20140234396 | EXTERNAL PATCHES CONTAINING ETOFENAMATE - The present invention provides to patches having excellent skin-permeability and therapeutic effect by the drug with lower irritation. In an external patch in which an adhesive layer containing an adhesive base and a drug are laminated with a backing, the external patch wherein the adhesive base contains 5-50% by weight of synthetic rubber polymer, 10-60% by weight of adhesive resin and 25-60% by weight of liquid paraffin, and the drug is etofenamate. According to the present invention, there is obtainable the patches having excellent skin-permeability and therapeutic effect by the drug with lower irritation. | 08-21-2014 |
20140255466 | COMPOSITION FOR ENHANCING TRANSDERMAL ABSORPTION OF DRUG AND PATCH PREPARATION - The present invention relates to a composition for enhancing transdermal absorption of a drug, containing a polyvalent alcohol having 3 to 8 carbon atoms, an organic acid having 2 to 20 carbon atoms, and a higher alcohol having 12 to 20 carbon atoms, and a patch preparation containing a support and a drug-containing adhesive layer containing the composition on one surface of the support. | 09-11-2014 |
20140271799 | TRANSDERMAL ADMINISTRATION OF FENTANYL AND ANALOGS THEREOF - A method and a non-rate controlled, monolithic, subsaturated patch for transdermally administering fentanyl and analogs thereof, for analgetic purposes, to a subject through skin over an extended period of time are disclosed. | 09-18-2014 |
20140294920 | TRANSDERMAL PROPRANOLOL PATCH FOR TREATMENT OF MALIGNANT MELANOMA - A transdermal d propranolol or racemic propranolol patch for use as an adjunct to surgery in the treatment of malignant melanoma and/or tattoo related applications are herein disclosed. | 10-02-2014 |
20140302118 | HYDROUS ADHESIVE SKIN PATCH - The purpose of the present invention is to provide a hydrous adhesive skin patch which contains lidocaine and can be applied in a uniform thickness easily. This hydrous adhesive skin patch comprises a support and an adhesive agent layer arranged on the support, wherein lidocaine or a pharmacologically acceptable salt thereof, a hydrophilic adhesive agent, and diethylene glycol or a diethylene glycol monoalkyl ether are contained in the adhesive agent layer. The diethylene glycol monoalkyl ether is preferably at least one compound selected from the group consisting of diethylene glycol monomethyl ether, diethylene glycol monoethyl ether and diethylene glycol monobutyl ether. | 10-09-2014 |
20140322300 | PATCH - A patch comprising a support layer and an adhesive agent layer, wherein
| 10-30-2014 |
20140335151 | PATCH CONTAINING NON-STEROIDAL ANTI-INFLAMMATORY DRUG - The present invention is directed to a patch containing a non-steroidal anti-inflammatory drug including an adhesive layer composed of a transdermal preparation on a support, the transdermal preparation including a) 10 to 40% by weight of a non-aqueous base material based on the total weight of the transdermal preparation, b) 1 to 10% by weight of a non-steroidal anti-inflammatory drug based on the total weight of the transdermal preparation, and c) a polyethylene glycol component composed of 0.3 to 5% by weight of a low molecular weight polyethylene glycol based on the total weight of the transdermal preparation, and 1 to 10% by weight of a high molecular weight polyethylene glycol based on the total weight of the transdermal preparation. | 11-13-2014 |
20140370078 | Topical and Transdermal Delivery of HIF-1 Modulators to Prevent and Treat Chronic Wounds - Compositions and methods are provided for the prevention and treatment of chronic wounds, including, without limitation, pressure ulcers and diabetic ulcers, by transdermal delivery of an agent that increases activity of HIF-1α in the wound. | 12-18-2014 |
20150017226 | TOLTERODINE-CONTAINING ADHESIVE PATCH - The present invention provides a tolterodine-containing patch in which an adhesive layer is laminated on a backing, characterized in that the adhesive layer is obtainable by adding tolterodine to an adhesive base comprising a rubber adhesive, a tackifier resin, and a softener, wherein the tolterodine is present in the form of a free base in the adhesive base. | 01-15-2015 |
20150030666 | ADHESIVE SKIN PATCH - The present invention provides an adhesive skin patch containing a support and an adhesive layer containing a drug which is formed on the support, wherein the adhesive layer comprises a thermoplastic elastomer, a liquid component in an amount exceeding 300 parts by weight per 100 parts by weight of the thermoplastic elastomer, a therapeutic drug having an anticholinergic activity or a salt thereof for overactive bladder as a drug, (A) a non-volatile hydrocarbon oil as a liquid component, and one or more kinds selected from the group consisting of (B) an amide solvent, (C) an alcohol solvent and (D) a liquid organic acid as a liquid component, or a fatty acid salt, and optionally comprises a tackifier at a content of not more than 10 wt % of the adhesive layer. | 01-29-2015 |
20150037394 | DRUG DELIVERY FORMULATIONS - Mixtures of C | 02-05-2015 |
20150037395 | TRANSDERMAL HORMONE DELIVERY SYSTEM: COMPOSITIONS AND MTEHODS - A transdermal hormone delivery system (THDS) is disclosed. The THDS is useful for control of fertility and as therapy for a variety of diseases and conditions treatable by robust delivery of progestin and estrogen hormones, particularly the progestin, levonorgestrel. The THDS comprises a backing layer, an adjoining adhesive polymer matrix comprising an effective amount of at least a progestin hormone, delivery of which is enhanced by one or more skin permeation enhancing agents present in pre-determined amounts. The THDS is capable of providing effective daily doses of progestin and estrogen hormones from a small surface area in contact with the skin, e.g., less than 20 square centimeters. Methods of fertility control and various types of hormone replacement therapy utilizing the THDS are also disclosed. | 02-05-2015 |
20150064232 | TRANSDERMAL ABSORPTION PREPARATION - [Problem] To provide a transdermal absorption preparation exhibiting excellent transdermal absorbability for 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide or a pharmaceutically acceptable salt thereof. | 03-05-2015 |
20150104497 | Topical Sphingosine-1-Phosphate Receptor Agonist Formulations and Methods of Using the Same - Topical sphingosine-1-phosphate receptor agonist active agent formulations are provided. Aspects of the transdermal formulations include an amount of a sphingosine-1-phosphate receptor agonist active agent in combination with a topical delivery vehicle, e.g., a topical patch that includes an adhesive layer and a backing layer. Also provided are methods of topically delivering a therapeutically effective amount of a sphingosine-1-phosphate receptor agonist active agent to a subject, e.g., to treat a subject for a disease condition, such as an immune system disorder like multiple sclerosis, a hyperproliferative dermatological disorder, e.g., psoriasis, acne, etc. Packaged topical formulations, kits including such formulations, and methods of making such formulations are also provided. | 04-16-2015 |
20150104498 | COMPOSITIONS AND KITS FOR THE REMOVAL OF IRRITATING COMPOUNDS FROM BODILY SURFACES - The invention provides compositions, methods and kits for the removal of harmful or irritating substances from bodily surfaces. Kits may include a composition containing capsaicin and a capsaicin-cleansing composition, e.g., a composition in which capsaicin is soluble. | 04-16-2015 |
20150104499 | TRANSDERMAL PATCH AND METHOD FOR DELIVERY OF VITAMIN B12 - The present invention is directed to compositions and devices for transdermally administering vitamin B | 04-16-2015 |
20150110852 | SHEET AND LIQUID COMBINATION SYSTEMS FOR DERMAL DELIVERY OF LIDOCAINE, DICLOFENAC, AND OTHER DRUGS - A system for dermal delivery of lidocaine, bupivacaine, diclofenac, or ketoprofen is provided which comprises at least two components, for example, a sheet of a solid and flexible material, and a vehicle liquid comprising a solvent and optionally other ingredients. A drug, selected from group consisting of lidocaine, bupivacaine, diclofenac, and ketoprofen, can be impregnated in the sheet or contained in the vehicle liquid. These two components can be stored separately and joined either shortly before or at the time of application. To use the system, the vehicle liquid may be applied either on the target skin area or on the sheet, and the sheet may then be applied on the target skin area so that the vehicle liquid is positioned between the sheet and the skin and brought into contact with the ingredients impregnated in the sheet. | 04-23-2015 |
20150118285 | PHARMACEUTICAL CARRIER DEVICE SUITABLE FOR DELIVERY OF PHARMACEUTICAL COMPOUNDS TO MUCOSAL SURFACES - The present invention relates to a pharmaceutical delivery device for application of a pharmaceutical to mucosal surfaces. The device comprises an adhesive layer and a non-adhesive backing layer, and the pharmaceutical may be provided in either or both layers. Upon application, the device adheres to the mucosal surface, providing localized drug delivery and protection to the treatment site. The kinetics of erodability are easily adjusted by varying the number of layers and/or the components. | 04-30-2015 |
20150297556 | TRANSDERMAL CANNABINOID PATCH - The present invention includes a transdermal patch which contains a pharmaceutically effective amount of a cannabinoid for delivery of the cannabinoid to the bloodstream of a user. The patch may comprise the following components: a backing; and a skin-adhesive polymer matrix attached to one side of the backing, which includes a cannabinoid, a carrier agent, a terpene, and a permeation agent. The cannabinoid is capable of diffusing from the matrix in the transdermal patch into the bloodstream of the user, and may be used in methods for treating a patient suffering from a condition such as pain, nausea and emesis, convulsions, muscle spasm, inflammation, depression, and cachexia. | 10-22-2015 |
20150313851 | COMPOSITION FOR THE TRANSDERMAL DELIVERY OF FENTANYL - A transdermal drug delivery composition comprises an acrylate copolymer and from about 8% to about 30% by weight fentanyl. A transdermal fentanyl delivery composition comprising methyl laurate or tetraglycol as a permeation enhancer is also provided. The transdermal drug delivery compositions can be used to make a transdermal drug delivery device for the delivery of fentanyl. | 11-05-2015 |
20160022627 | TRANSDERMAL CANNABINOID PATCH - The present invention includes a transdermal patch which contains a pharmaceutically effective amount of a cannabinoid for delivery of the cannabinoid to the bloodstream of a user. The patch may comprise the following components: a backing; and a skin-adhesive polymer matrix attached to one side of the backing, which includes a cannabinoid, a carrier agent, a terpene, and a permeation agent. The cannabinoid is capable of diffusing from the matrix in the transdermal patch into the bloodstream of the user, and may be used in methods for treating a patient suffering from a condition such as pain, nausea and emesis, convulsions, muscle spasm, inflammation, depression, and cachexia. | 01-28-2016 |
20160024481 | TOPICAL COMPOSITIONS COMPRISING DIAMINOOXIDASE FOR THE TREATMENT OR PREVENTION OF DISEASES ASSOCIATED WITH HIGH HISTAMINE LEVELS WHICH INVOLVE AN INCREASE IN PAIN - The present invention relates to a pharmaceutical, cosmetic or dermo-cosmetic composition that comprises DAO, for use in the prevention or treatment of diseases or pathological conditions associated with high levels of histamine in blood which involve an increase in pain, preferably fibromyalgia, characterised in that the application of the composition is topical. | 01-28-2016 |
20160051487 | COMPOSITIONS AND METHODS FOR TRANSDERMAL DELIVERY OF HORMONES AND OTHER MEDICINAL AGENTS - The invention provides transdermal delivery systems, medical kits, and methods for using the transdermal delivery systems and kits for medical applications, such as delivery of contraceptive agents to control fertility. | 02-25-2016 |
20160074336 | Transdermal Therapeutic System Comprising an Adhesive Layer Method for Siliconizing the Back Layer of the System and Use of Said Back Layer - The invention generally relates to a transdermal therapeutic system which comprises a backing layer, an adhesive layer, a polymer layer and a removable protective layer. The adhesive layer is an organosiloxane layer that is anchored to the backing layer by siliconization. | 03-17-2016 |
20160095926 | DEVICE FOR TRANSDERMAL ADMINISTRATION OF DRUGS INCLUDING ACRYLIC BASED POLYMERS - A transdermal delivery system is provided where the drug delivery rates, onset and profiles of at least one active agent are controlled by selectively manipulating the monomeric make up of an acrylic-based polymer in the transdermal drug delivery system. The drug carrier composition may be comprised of (a) one or more acrylic-based polymers having one or more different monomers selected from the group consisting of hard and soft monomers; (b) one or more silicone-based polymers; and (c) one or more active agents where the device provides a desired solubility for the active agent and controls drug delivery rates, onset and profiles of at least one active agent. | 04-07-2016 |
20160101061 | PHARMACEUTICAL CARRIER DEVICE SUITABLE FOR DELIVERY OF PHARMACEUTICAL COMPOUNDS TO MUCOSAL SURFACES - The present invention relates to a pharmaceutical delivery device for application of a pharmaceutical to mucosal surfaces. The device comprises an adhesive layer and a non-adhesive backing layer, and the pharmaceutical may be provided in either or both layers. Upon application, the device adheres to the mucosal surface, providing localized drug delivery and protection to the treatment site. The kinetics of erodability are easily adjusted by varying the number of layers and/or the components. | 04-14-2016 |
20160106797 | TOPICAL TREATMENT OF SHINGLES - The present invention relates to a homeopathic composition that may be used for treatment of chronic moderate to severe pain associated with virally driven neuropathies. More particularly, the present disclosure and claims provide a treatment of the pain symptoms of shingles, herpes zoster. In some embodiments, the application of the homeopathic composition may reduce length of the outbreak, severity of symptoms, and long term effects, such as nerve damage or skin discoloration. | 04-21-2016 |
20160120822 | COMPOSITION CONTAINING ROTIGOTINE AND USE THEREOF AND TRANSDERMAL PATCH CONTAINING THE COMPOSITION - A Rotigotine-containing composition having a matrix mixture system formed from a polyvinylpyrrolidone and a combination of an acrylic pressure-sensitive adhesive with a silicone pressure-sensitive adhesive. The polyvinylpyrrolidone may be present in an amount of about 1-10% by weight in the matrix mixture system. The acrylic pressure-sensitive adhesive may be present in an amount of about 1-25% by weight in the matrix mixture system. The silicone pressure-sensitive adhesive may be present in an amount of about 65-98% by weight in the matrix mixture system. The composition further includes 1-40% of Rotigotine on the basis of the total weight of the composition. The composition provides improved properties in the solubility, release and initial penetration level of Rotigotine. Also disclosed is a transdermal patch that includes the Rotigotine-containing composition, as well as methods of manufacturing and using the Rotigotine-containing composition. | 05-05-2016 |
20160151300 | Method of Producing and Introducing a Far Infrared Device By Way of Adhesive Tape | 06-02-2016 |
20160184235 | COMPOSITION FOR THE TRANSDERMAL DELIVERY OF FENTANYL - A transdermal drug delivery composition comprises an acrylate copolymer and from about 8% to about 30% by weight fentanyl. A transdermal fentanyl delivery composition comprising methyl laurate or tetraglycol as a permeation enhancer is also provided. The transdermal drug delivery compositions can be used to make a transdermal drug delivery device for the delivery of fentanyl. | 06-30-2016 |
20160184240 | Transdermal Compositions Comprising an Active Agent Layer and An Active Agent Conversion Layer - Transdermal compositions are provided. Aspects of the transdermal compositions include: an active agent layer and a conversion layer, where the conversion layer includes a weak base and, optionally, a carboxylated component. Also provided are methods of using the transdermal compositions and kits containing the transdermal compositions. | 06-30-2016 |
20160184246 | TRANSDERMAL DRUG DELIVERY SYSTEMS FOR AGOMELATINE - Described are transdermal drug delivery systems for the transdermal administration of agomelatine. Methods of making and using such systems also are described. | 06-30-2016 |
20160199317 | ESTRADIOL CONTAINING TRANSDERMAL DRUG DELIVERY SYSTEMS AND COMPOSITIONS | 07-14-2016 |
20160250156 | TRANSDERMAL PREPARATION | 09-01-2016 |
20190142763 | MICROCELL SYSTEMS FOR DELIVERING HYDROPHILIC ACTIVE MOLECULES | 05-16-2019 |